Phase I, Open-label, Single Dose Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics (PK) of Evobrutinib (M2951) Compared to Normal Renal Function in Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2018
At a glance
- Drugs Evobrutinib (Primary)
- Indications Autoimmune disorders; Encephalomyelitis; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 27 Nov 2018 Planned End Date changed from 6 Dec 2018 to 27 Feb 2019.
- 27 Nov 2018 Planned primary completion date changed from 6 Dec 2018 to 27 Feb 2019.
- 27 Nov 2018 Status changed from completed to recruiting.